ALLO ALLOGENE THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, ALLOGENE THERAPEUTICS INC reported revenue of $4.64M, net income of −$42.7M and diluted EPS of −$0.13; for the fiscal year ended December 2025 revenue was $0, down 100.0% on the year before.

ALLO annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $0, gross profit n/a, operating income −$209M, net income −$191M (margin n/a), EPS −$0.87
• Fiscal year ended Dec 2024: revenue $22.0K, gross profit n/a, operating income −$273M, net income −$258M (margin -1170863.6%), EPS −$1.32
• Fiscal year ended Dec 2023: revenue $95.0K, gross profit n/a, operating income −$328M, net income −$327M (margin -344489.5%), EPS −$2.09
• Fiscal year ended Dec 2022: revenue $156K, gross profit n/a, operating income −$336M, net income −$340M (margin -218214.1%), EPS −$2.38
• Fiscal year ended Dec 2021: revenue $114M, gross profit n/a, operating income −$180M, net income −$182M (margin -159.6%), EPS −$1.34

ALLO quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $4.64M, net income −$42.7M, EPS −$0.13
• Quarter ended Mar 31, 2026: revenue n/a, net income −$42.6M, EPS −$0.18
• Quarter ended Dec 31, 2025 (from the annual report): revenue $0, net income −$38.8M, EPS −$0.17
• Quarter ended Sep 30, 2025: revenue $0, net income −$41.4M, EPS −$0.19
• Quarter ended Jun 30, 2025: revenue $0, net income −$50.9M, EPS −$0.23
• Quarter ended Mar 31, 2025: revenue $0 (down 100.0% year over year), net income −$59.7M, EPS −$0.28
• Quarter ended Dec 31, 2024 (from the annual report): revenue $0 (down 100.0% year over year), net income −$59.9M, EPS −$0.27
• Quarter ended Sep 30, 2024: revenue $0 (down 100.0% year over year), net income −$66.3M, EPS −$0.32
• Quarter ended Jun 30, 2024: revenue $0 (down 100.0% year over year), net income −$66.4M, EPS −$0.35
• Quarter ended Mar 31, 2024: revenue $22.0K (down 26.7% year over year), net income −$65.0M, EPS −$0.38
• Quarter ended Dec 31, 2023 (from the annual report): revenue $21.0K (down 19.2% year over year), net income −$85.8M, EPS −$0.49
• Quarter ended Sep 30, 2023: revenue $22.0K (down 18.5% year over year), net income −$62.3M, EPS −$0.37
• Quarter ended Jun 30, 2023: revenue $22.0K (down 65.6% year over year), net income −$79.2M, EPS −$0.54
• Quarter ended Mar 31, 2023: revenue $30.0K (down 23.1% year over year), net income −$100.0M, EPS −$0.69
• Quarter ended Dec 31, 2022 (from the annual report): revenue $26.0K (down 100.0% year over year), net income −$97.3M, EPS −$0.67
• Quarter ended Sep 30, 2022: revenue $27.0K (down 44.9% year over year), net income −$84.2M, EPS −$0.59
• Quarter ended Jun 30, 2022: revenue $64.0K (up 45.5% year over year), net income −$80.3M, EPS −$0.56
• Quarter ended Mar 31, 2022: revenue $39.0K (down 99.9% year over year), net income −$78.6M, EPS −$0.56
• Quarter ended Dec 31, 2021 (from the annual report): revenue $75.7M, net income $86.0K, EPS $0.01
• Quarter ended Sep 30, 2021: revenue $49.0K, net income −$78.2M, EPS −$0.57

ALLO cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$149M, share buybacks n/a, dividends $0.00 per share
• Fiscal year ended Dec 2024: operating cash flow −$200M, share buybacks n/a, dividends $0.00 per share
• Fiscal year ended Dec 2023: operating cash flow −$238M, share buybacks n/a, dividends $0.00 per share
• Fiscal year ended Dec 2022: operating cash flow −$221M, share buybacks n/a, dividends $0.00 per share
• Fiscal year ended Dec 2021: operating cash flow −$185M, share buybacks n/a, dividends $0.00 per share

ALLO balance sheet

• Jun 30, 2026: cash $38.6M, total assets $550M, total liabilities $114M, shareholders' equity $436M
• Mar 31, 2026: cash $30.3M, total assets $396M, total liabilities $117M, shareholders' equity $279M
• Dec 31, 2025: cash $51.7M, total assets $416M, total liabilities $123M, shareholders' equity $293M
• Sep 30, 2025: cash $37.8M, total assets $440M, total liabilities $124M, shareholders' equity $315M
• Jun 30, 2025: cash $52.3M, total assets $471M, total liabilities $126M, shareholders' equity $345M
• Mar 31, 2025: cash $42.5M, total assets $508M, total liabilities $123M, shareholders' equity $385M
• Dec 31, 2024: cash $75.2M, total assets $549M, total liabilities $127M, shareholders' equity $422M
• Sep 30, 2024: cash $51.2M, total assets $589M, total liabilities $125M, shareholders' equity $464M

What is ALLO's revenue?

ALLOGENE THERAPEUTICS INC reported $0 of revenue for the fiscal year ended December 2025.

Is ALLO profitable?

No. ALLOGENE THERAPEUTICS INC lost $165M over the last four quarters.

What is ALLO's EPS?

Diluted earnings per share over the last four quarters were −$0.67; −$0.13 in the latest quarter.

ALLO ownership and insider trades · All stocks